As of 2025-05-15, the Relative Valuation of Pacira Biosciences Inc (PCRX) is (47.26) USD. This relative valuation is based on P/E multiples. With the latest stock price at 24.45 USD, the upside of Pacira Biosciences Inc based on Relative Valuation is -293.3%.
The range of the Relative Valuation is (42.82) - (50.49) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.9x - 30.6x | 26.9x |
| Forward P/E multiples | 18.9x - 25.8x | 21.4x |
| Fair Price | (42.82) - (50.49) | (47.26) |
| Upside | -275.1% - -306.5% | -293.3% |
| Date | P/E |
| 2025-05-14 | -12.49 |
| 2025-05-13 | -11.96 |
| 2025-05-12 | -12.82 |
| 2025-05-09 | -12.84 |
| 2025-05-08 | -12.73 |
| 2025-05-07 | -12.87 |
| 2025-05-06 | -12.85 |
| 2025-05-05 | -13.19 |
| 2025-05-02 | -13.52 |
| 2025-05-01 | -13.67 |
| 2025-04-30 | -13.75 |
| 2025-04-29 | -13.80 |
| 2025-04-28 | -13.87 |
| 2025-04-25 | -13.14 |
| 2025-04-24 | -13.29 |
| 2025-04-23 | -12.88 |
| 2025-04-22 | -13.01 |
| 2025-04-21 | -13.24 |
| 2025-04-17 | -12.60 |
| 2025-04-16 | -12.51 |
| 2025-04-15 | -12.71 |
| 2025-04-14 | -12.76 |
| 2025-04-11 | -12.55 |
| 2025-04-10 | -12.11 |
| 2025-04-09 | -13.21 |
| 2025-04-08 | -13.42 |
| 2025-04-07 | -11.71 |
| 2025-04-04 | -11.80 |
| 2025-04-03 | -12.41 |
| 2025-04-02 | -12.72 |
| 2025-04-01 | -12.30 |
| 2025-03-31 | -12.70 |
| 2025-03-28 | -12.73 |
| 2025-03-27 | -12.93 |
| 2025-03-26 | -12.48 |
| 2025-03-25 | -12.54 |
| 2025-03-24 | -12.69 |
| 2025-03-21 | -12.34 |
| 2025-03-20 | -12.17 |
| 2025-03-19 | -12.41 |
| 2025-03-18 | -12.10 |
| 2025-03-17 | -11.91 |
| 2025-03-14 | -11.69 |
| 2025-03-13 | -11.60 |
| 2025-03-12 | -11.26 |
| 2025-03-11 | -11.84 |
| 2025-03-10 | -11.80 |
| 2025-03-07 | -11.94 |
| 2025-03-06 | -12.19 |
| 2025-03-05 | -12.01 |